-- DRI Healthcare Trust (DHT-UN.TO) 周三交易结束后注意到 KalVista Therapeutics 宣布已与国际研发型生物制药集团 Chiesi Group 达成最终收购协议，并表示正在评估该交易对自身的影响。 DRI Healthcare 根据与 KalVista 签订的特许权使用费协议，有权获得 Ekterly（sebetralstat）所有制剂的全球净销售额。该公司表示，根据公开信息，如果 KalVista 的交易完成，可能会构成 DRI Healthcare 特许权使用费协议项下的控制权变更。 该公司补充道：“DRI Healthcare 目前正在审查已宣布的交易，并评估其在特许权使用费协议项下的权利和义务，包括可能与该交易相关的卖出期权和回购条款。目前尚未决定 DRI Healthcare 可能就该交易采取的任何行动。” DRI股票在多伦多证券交易所收盘上涨0.04美元，至16.45美元。
Related Articles
Asia
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
$ASX:EOS
Asia
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
$ASX:REG
Research
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.
$MDLZ